An observational study in Medical Condition Requiring Extracorporeal Organ Support, sponsored by University Hospital Freiburg. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2023-04-13.
Sponsored by University Hospital Freiburg · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Respiratory Distress Syndrome with a site in Germany — 7 open to participants now, 8 under way, 1 of them phase 3. Respiratory Distress Syndrome · Germany.
Among the 48 studies in Respiratory Distress Syndrome with a site in Germany, this one is the 5th largest by planned enrollment of the 21 observational ones that give a count, is one of 5 that started in 2014, is one of 22 observational ones, and was the 46th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →7 of the 48 studies in Respiratory Distress Syndrome with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Tuebingen · Sites in Germany
Ages 18+
BioAegis Therapeutics Inc. · Sites in Germany, United States, Belgium and 10 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Germany, Switzerland
Ages 23 wk–31 wk
University Hospital Tuebingen · Sites in Germany
Ages 18+
AstraZeneca · Sites in Germany, United States, Argentina and 36 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 7
First in 2003; this study’s year is marked. 5 started in 2014.
This study's planned enrollment of 1,500 is above the median of 100 across 476 observational studies indexed under Respiratory Distress Syndrome.
Median enrollment 114 across the 26 interventional studies, 132 across the 21 observational. Of the 28 that completed or were terminated, 4 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 48 have an industry lead sponsor. The 10 most frequent:
University Hospital Freiburg is the lead sponsor of 94 studies on the registry; 18 are open to participants now.
University Hospital Freiburg has 2 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Respiratory Distress Syndrome with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05947955BioAegis Therapeutics Inc.Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS) | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 48 studies in Respiratory Distress Syndrome with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective registry collecting pseudonymized clinical and treatment data from all patients treated with extracorporeal organ support (i.e., VV ECMO, VA ECMO, ECPR, Impella, IABP, and others) on the wards of the Department of Interdisciplinary Medical Intensive Care at the Freiburg University Medical Center.
All patients receiving extracorporeal organ support and being treated in the Department of Interdisciplinary Medical Intensive Care of the Freiburg University Medical Center
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Hospital survival
Survival of index hospitalization (yes/no)
Time frame: 30 days
Mesenteric ischemia
Occurrence of mesenteric ischemia
Time frame: 30 days
Fluid balance
Patient fluid balance (difference between fluid input and output)
Time frame: 7 days
ECMO run-time
Duration of ECMO support
Time frame: 60 days
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2014 (actual). Primary completion is estimated for Dec 2030, 200 months after the start.
Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 200 months is above that.
Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
University Hospital Freiburg